This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

First in Man Study With SLV342

This study has been terminated.
(Terminated on 14 Sep 2010 due to strategic considerations)
Quintiles, Inc.
Information provided by (Responsible Party):
Abbott ( Abbott Products ) Identifier:
First received: September 25, 2009
Last updated: August 24, 2011
Last verified: August 2011
First in man study with single and multiple rising doses with SLV342

Condition Intervention Phase
Pharmacokinetics Drug: SLV342 Drug: placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV342 in Young Healthy Male Subjects

Further study details as provided by Abbott ( Abbott Products ):

Primary Outcome Measures:
  • Safety and tolerability parameters: adverse event, vital signs, 12-Lead ECG, continuous lead II ECG monitoring, laboratory safety variables and physical examination [ Time Frame: 28 Days ]

Secondary Outcome Measures:
  • Pharmacokinetic parameters: Plasma: Cmax, tmax, AUC, t½, λz, CL/F, and Vz/F. Urine: Aeurine, fe, and CLR [ Time Frame: 28 days ]
  • Pharmacodynamic parameters: biochemistry and 24 h Holter monitoring [ Time Frame: 28 days ]
  • Midazolam PK parameters [ Time Frame: 24 hours ]

Enrollment: 48
Study Start Date: January 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
SLV342 suspension or capsule
Drug: SLV342
25 mg once daily - Maximal Tolerated Dose
Placebo Comparator: B
matching placebo
Drug: placebo
matching placebo


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • Healthy

Exclusion Criteria

  • Not healthy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00985478

United Kingdom
Site Reference ID/Investigator# 61142
London, United Kingdom, SE1 1YR
Sponsors and Collaborators
Abbott Products
Quintiles, Inc.
Study Director: Ingrid Meuwsen, MS Abbott Healthcare Products B.V
  More Information

Responsible Party: Abbott Products Identifier: NCT00985478     History of Changes
Other Study ID Numbers: S342.1.001
2009-014245-88 ( EudraCT Number )
Study First Received: September 25, 2009
Last Updated: August 24, 2011

Keywords provided by Abbott ( Abbott Products ):
First in Man
Atherosclerosis processed this record on August 18, 2017